Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Somatostatin receptor type 3 | ||
Ligand | BDBM50075273 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEBML_200701 | ||
Ki | >10000±n/a nM | ||
Citation | Pasternak, A; Pan, Y; Marino, D; Sanderson, PE; Mosley, R; Rohrer, SP; Birzin, ET; Huskey, SE; Jacks, T; Schleim, KD; Cheng, K; Schaeffer, JM; Patchett, AA; Yang, L Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett9:491-6 (1999) [PubMed] | ||
More Info.: | Get all data from this article, Assay Method | ||
Somatostatin receptor type 3 | |||
Name: | Somatostatin receptor type 3 | ||
Synonyms: | SOMATOSTATIN SST3 | SS-3-R | SS3-R | SS3R | SSR-28 | SSR3_HUMAN | SSTR3 | Somatostatin receptor type 3 (SSTR3) | ||
Type: | Protein | ||
Mol. Mass.: | 45855.97 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P32745 | ||
Residue: | 418 | ||
Sequence: |
| ||
BDBM50075273 | |||
n/a | |||
Name | BDBM50075273 | ||
Synonyms: | (2R,3S)-N-(5-Amino-[1,3]dioxan-2-ylmethyl)-3-(1H-indol-3-yl)-N-methyl-2-[2-oxo-3-(1-phenyl-piperidin-3-yl)-imidazolidin-1-yl]-butyramide | CHEMBL435631 | ||
Type | Small organic molecule | ||
Emp. Form. | C32H42N6O4 | ||
Mol. Mass. | 574.7137 | ||
SMILES | C[C@H]([C@@H](N1CCN(C2CCCN(C2)c2ccccc2)C1=O)C(=O)N(C)C[C@H]1OC[C@H](N)CO1)c1c[nH]c2ccccc12 |wU:2.2,26.28,wD:29.32,1.0,(-1.79,4.28,;-1.77,2.74,;-.43,1.97,;.89,2.75,;.87,4.29,;3.54,4.3,;3.55,2.77,;4.9,2.04,;4.96,.5,;6.32,-.22,;7.63,.57,;7.58,2.11,;6.22,2.84,;8.89,2.93,;8.83,4.47,;10.14,5.28,;11.5,4.54,;11.54,3,;10.24,2.19,;2.22,2,;2.24,.46,;-.43,.44,;1.1,.43,;-1.21,-.89,;-2.75,-.87,;-.46,-2.22,;-1.24,-3.54,;-.47,-4.88,;-1.25,-6.21,;-2.8,-6.2,;-3.58,-7.51,;-3.56,-4.86,;-2.77,-3.53,;-3.1,1.96,;-3.09,.43,;-4.42,-.36,;-5.75,.41,;-7.08,-.36,;-8.43,.41,;-8.43,1.96,;-7.08,2.73,;-5.75,1.96,)| | ||
Structure |